Structured evidence table for Sulforaphane Metabolic Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sulforaphane Metabolic Health Randomized Trial | The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing [,]. | 1 | Kassar Omar (2025) | Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
| Sulforaphane Metabolic Health Randomized Trial | Patients with schizophrenia have a mortality rate of 2-3-fold compared to healthy people, with a reduced expected life of 10–20 years []. | 1 | Kassar Omar (2025) | Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
| Sulforaphane Metabolic Health Randomized Trial | The main goal of antipsychotics is restoring the patient’s normal daily functioning, followed by maintenance doses of therapy to prevent the risk of hospitalization and improve quality of life []. | 1 | Kassar Omar (2025) | Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
| Sulforaphane Metabolic Health Randomized Trial | 1 2 3 4 5 6 7 Schizophrenia is one of the most prevalent long-term disabling psychiatric disorders, affecting around 0.7% to 1% of the general population []. | 1 | Kassar Omar (2025) | Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials |
| Sulforaphane Metabolic Health Randomized Trial | Excess accumulation of MG can promote protein glycation and the formation of advanced glycation end-products (AGEs), which have been associated with oxidative stress, inflammation, mitochondrial dysfunction, and cellular damage. | 4 | Khan MA (2026) | Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases. |
| Sulforaphane Metabolic Health Randomized Trial | Evidence from preclinical and limited human studies suggests that these compounds may help reduce MG burden and AGE formation, although their effects are often indirect and context-dependent. | 4 | Khan MA (2026) | Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases. |
| Sulforaphane Metabolic Health Randomized Trial | By integrating mechanistic insights with emerging in vivo and clinical evidence, this work highlights the potential, while acknowledging the limitations, of targeting Glo1 as a translational strategy for managing glycation-associated disorders. | 4 | Khan MA (2026) | Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases. |
| Sulforaphane Metabolic Health Randomized Trial | Methylglyoxal (MG) is a reactive dicarbonyl compound generated mainly as a byproduct of glycolysis. | 4 | Khan MA (2026) | Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases. |
Source documents